Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity

作者：Yonghua Li, Min Sheng, Weijie Li, Simin Liu, Botao Wang, Bing Liu, Mei Luo, Xiao Zhou, Qiaoxi Xia, Shihong Hong, Ziyuan Zheng, Shi‐Yuan Cheng, Xiaobing Jiang, Jun Jun Li, Tianzhi Huang · 发表于：Nature Communications · 年份：2025 · DOI：10.1038/s41467-025-67119-3 · 被引用次数：3 · 研究领域：Autophagy in Disease and Therapy、interferon and immune responses、Endoplasmic Reticulum Stress and Disease

Chaperone-mediated autophagy (CMA) is a selective autophagic process essential for maintaining cellular quality and responding to stress. Dysregulation of the CMA pathway is increasingly recognized in various cancers, yet the mechanisms behind CMA hyperactivation in cancer cells remain unclear. Here, we show that CMA is upregulated in patient-derived glioblastoma stem cells (GSCs), indicated by a significant increase in the lysosomal abundance of the CMA receptor, lysosome-associated membrane protein 2 A (LAMP2A). This increase results from MST4-mediated phosphorylation of LAMP2A, enhancing its stability and promoting homotrimer formation while inhibiting degradation by Cathepsin A. CMA supports GSC proliferation and self-renewal by activating mTORC1 through the selective degradation of its negative regulators, TSC1 and TSC2. Additionally, CMA is involved in epigenetic silencing of the cGAS-STING pathway, promoting tumor immune escape via lysosomal degradation of the DNA demethylase TET3. Inhibition of CMA synergizes with immune checkpoint therapy in glioblastoma models, highlighting a potential therapeutic target. Chaperone-mediated autophagy (CMA) is often dysregulated in cancer, but its mechanisms remain unclear. This study reveals that MST4- mediated LAMP2A phosphorylation regulates CMA by stabilizing lysosomal LAMP2A, thereby promoting GBM tumorigenicity and immune evasion.